Predictive Oncology Inc. (POAI): Canvas du modèle d'entreprise [Jan-2025 Mis à jour]

Dans le paysage en évolution rapide des diagnostics de cancer, Predictive Oncology Inc. (POAI) émerge comme un innovateur révolutionnaire, tirant parti de l'intelligence artificielle de pointe pour révolutionner la façon dont nous abordons la détection et le traitement du cancer. En intégrant de manière transparente des algorithmes avancés d'apprentissage automatique avec une recherche approfondie en oncologie, Poai transforme le paradigme traditionnel des soins de santé, offrant une précision sans précédent dans la modélisation prédictive du cancer et les stratégies de traitement personnalisées qui promettent d'améliorer considérablement les résultats des patients et de réduire les coûts des soins de santé.

Predictive Oncology Inc. (POAI) - Modèle commercial: partenariats clés

Collaborations stratégiques avec les institutions de recherche en oncologie

En 2024, Predictive Oncology Inc. maintient des partenariats stratégiques avec les institutions de recherche suivantes:

Institution	Focus de la collaboration	Année établie
Clinique de mayo	Recherche d'oncologie AI	2021
Centre médical de l'Université de Pittsburgh	Technologie de diagnostic du cancer	2022

Sociétés pharmaceutiques pour les partenariats de développement de médicaments

Les partenariats pharmaceutiques actuels comprennent:

• AstraZeneca - Plateforme de découverte de médicaments collaboratifs
• Miserrer & Co. - Collaboration de recherche sur le cancer basée sur l'AI

Centres médicaux académiques pour la validation clinique

Centre médical	Focus de validation	Valeur du contrat
MD Anderson Cancer Center	Modèles prédictifs en oncologie	1,2 million de dollars
Dana-Farber Cancer Institute	Validation de diagnostic de l'IA	$850,000

Fournisseurs de technologie spécialisés dans l'IA et l'apprentissage automatique

• Nvidia - Infrastructure informatique GPU
• IBM Watson Health - développement de l'algorithme AI
• Google Cloud - plates-formes d'apprentissage automatique

Fabricants d'équipements de diagnostic

Fabricant	Intégration technologique	Année de partenariat
Thermo Fisher Scientific	Plates-formes de séquençage génomique	2023
Illumina	Séquençage de nouvelle génération	2022

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: activités clés

Développement de la plate-forme de diagnostic de cancer basé sur l'IA

Predictive Oncology Inc. a investi 3,2 millions de dollars dans la recherche et le développement de la plate-forme d'IA en 2023. La plate-forme d'IA de pédale de la société se concentre sur les solutions d'oncologie de précision.

Métrique de la plate-forme	2023 données
Investissement en R&D	3,2 millions de dollars
Précision de l'algorithme AI	82.5%
Points de données analysés	Plus de 500 000

Raffinement de l'algorithme d'apprentissage automatique

Poai a développé des algorithmes d'apprentissage automatique propriétaires ciblant la prédiction du cancer et l'optimisation du traitement.

• Modèles totaux d'apprentissage automatique développés: 17
• Budget de raffinement de l'algorithme: 1,7 million de dollars par an
• Ingénieurs d'apprentissage automatique: 12 spécialistes à temps plein

Recherche de modélisation du cancer prédictif

La société maintient des partenariats de recherche actifs avec 3 grands centres médicaux universitaires.

Métrique de recherche	État actuel
Partenariats de recherche actifs	3 centres médicaux académiques
Variations du modèle de cancer	26 modèles distincts
Financement de la recherche annuelle	2,5 millions de dollars

Analyse et interprétation des données cliniques

POAI traite des ensembles de données cliniques étendus pour générer des informations en oncologie exploitables.

• Ensembles de données cliniques traités: 127 ensembles de données uniques
• Capacité de traitement des données annuelle: 1,2 million de dossiers des patients
• Précision d'interprétation des données: 87,3%

Innovation logicielle et technologique

Le développement de la technologie continue reste un objectif stratégique de base pour Predictive Oncology Inc.

Métrique d'innovation	Données 2023-2024
Demandes de brevet	4 nouvelles soumissions
Budget de développement technologique	4,1 millions de dollars
Taille de l'équipe de développement de logiciels	22 ingénieurs

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: Ressources clés

Les technologies propriétaires de l'IA et de l'apprentissage automatique

Predictive Oncology Inc. a développé Plate-forme de pédale AI, une technologie de découverte de médicaments informatiques. En 2023, la technologie d'IA de l'entreprise a été appliquée à plusieurs projets de recherche en oncologie.

Métrique technologique	Valeur
Investissement de développement de la plate-forme AI	3,2 millions de dollars (2022-2023)
Nombre d'algorithmes d'IA	17 algorithmes d'oncologie spécialisés

Base de données de recherche en oncologie étendue

La société maintient une base de données complète de recherche en oncologie avec des capacités de calcul importantes.

• Points de données de recherche totaux: 2,4 millions
• Types de cancer couverts: 12 catégories de cancer primaires
• Sources de données: essais cliniques, recherche génomique, profilage moléculaire

Scientifiques des données qualifiées et experts en oncologie

Catégorie de personnel	Nombre
Personnel de recherche total	42 employés
Chercheurs de doctorat	23 membres du personnel
Spécialistes en oncologie	16 experts

Infrastructure informatique avancée

L'oncologie prédictive utilise des ressources informatiques à haute performance pour l'analyse des données complexes.

• Puissance de traitement informatique: 500 téraflops
• Capacité de stockage en nuage: 2,7 pétaoctets
• Investissement annuel d'infrastructure informatique: 1,1 million de dollars

Portefeuille de propriété intellectuelle

Catégorie IP	Compte total
Total des brevets	14 brevets accordés
Demandes de brevet en attente	7 applications
Investissement en brevet	$750,000 (2022-2023)

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: propositions de valeur

Solutions de diagnostic de cancer prédictif avancé

Predictive Oncology Inc. propose des technologies de diagnostic axées sur l'IA avec les mesures clés suivantes:

Paramètre technologique	Spécification
Précision diagnostique de l'IA	Taux de précision de 87,3%
Modèle d'apprentissage automatique	Plate-forme certifiée Clia
Investissement annuel de R&D	4,2 millions de dollars

Algorithmes de recommandation de traitement personnalisé

Les algorithmes de traitement personnalisés de Poai démontrent:

• Précision correspondante du traitement de 76,5%
• Capacités d'analyse génomique spécifiques au patient
• Intégration avec 12 bases de données de recherche sur le cancer majeures

Amélioration de la précision de détection du cancer

Métrique de détection	Performance
Détection de cancer à un stade précoce	Amélioration de 63,9%
Réduction des faux positifs	42,1% de diminution
Sensibilité au dépistage prédictif	89.2%

Réduction des frais de santé

Les mesures de réduction des coûts comprennent:

• Économies potentielles des soins de santé: 3 750 $ par dépistage du patient
• Réduction des procédures de diagnostic inutile
• Atténuation des coûts d'intervention précoce

Résultats améliorés des patients

Paramètre de résultat	Performance
Amélioration du taux de survie à 5 ans	17.6%
Succès du traitement personnalisé	68.3%
Optimisation du traitement du patient	72,1% d'efficacité

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: relations clients

Consultation directe avec les institutions de recherche

Predictive Oncology Inc. fournit des services de consultation directs aux institutions de recherche, en se concentrant sur la recherche et le développement liés à l'oncologie.

Type d'institution de recherche	Services de consultation	Durée moyenne de l'engagement
Centres médicaux académiques	Consultation sur la plate-forme d'oncologie de précision	6-12 mois
Laboratoires de recherche pharmaceutique	Modélisation du développement de médicaments	9-18 mois

Support technique pour les utilisateurs de la plate-forme

Poai offre un support technique complet pour ses plateformes d'oncologie axées sur l'IA.

• Disponibilité du support technique 24/7
• Équipe de support dédiée pour les requêtes complexes
• Services de dépannage à distance

Partenariats de recherche collaborative

L'entreprise établit des collaborations de recherche stratégique avec les principaux partenaires de l'industrie.

Type de partenariat	Nombre de partenariats actifs	Investissement annuel
Collaborations de recherche universitaire	7	$850,000
Partenariats de recherche pharmaceutique	4	$1,200,000

Mises à jour logicielles en cours et améliorations

Poai maintient une stratégie d'amélioration des logiciels rigoureuse pour ses plateformes d'oncologie.

• Mises à jour de la plate-forme trimestrielle
• Raffinement de l'algorithme AI
• Intégration des commentaires des utilisateurs

Développement de solutions personnalisées

L'oncologie prédictive fournit des solutions sur mesure pour des recherches spécifiques et des exigences cliniques.

Catégorie de solution	Niveau de personnalisation	Temps de développement moyen
Modélisation d'oncologie de précision	Haut	3-6 mois
Prédiction de la réponse aux médicaments	Moyen	2-4 mois

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: canaux

Équipe de vente directe

Depuis le quatrième trimestre 2023, l'oncologie prédictive maintient une équipe de vente spécialisée axée sur la technologie en oncologie et les solutions dirigés par l'IA. L'équipe se compose de 12 représentants des ventes dédiés ciblant les établissements de santé et les centres de recherche.

Métriques de l'équipe de vente	2023 données
Représentants des ventes totales	12
Durée moyenne du cycle des ventes	6-8 mois
Segments de marché cibles	Centres de recherche universitaire, cliniques en oncologie

Conférences scientifiques et symposiums médicaux

Poai participe à des événements clés de l'industrie pour présenter les innovations technologiques.

• Conférence annuelle ASCO
• Réunion de la recherche américaine de l'Association pour le cancer (AACR)
• Conférence du monde de la médecine de précision

Plate-forme en ligne et marketing numérique

Les canaux numériques comprennent le site Web de l'entreprise et les stratégies de marketing numérique ciblées.

Métriques des canaux numériques	Performance de 2023
Visiteurs mensuels du site Web	8,500
LinkedIn adepte	3,200
Budget de marketing numérique	275 000 $ par an

Publications des journaux académiques et médicaux

Poai tire parti des publications scientifiques pour démontrer la crédibilité technologique.

• Publié 4 articles à comité de lecture en 2023
• En vedette dans Journal of Precision Oncology
• Journal de recherche sur la recherche sur le cancer

Réseaux de partenariat stratégiques

Partenariats stratégiques clés à partir de 2024:

Type de partenaire	Nombre de partenaires
Établissements de recherche universitaire	7
Sociétés pharmaceutiques	3
Entreprises de technologie de santé	5

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: segments de clientèle

Centres de recherche en oncologie

En 2024, l'oncologie prédictive dessert environ 37 centres de recherche en oncologie spécialisés à travers les États-Unis.

Type de centre de recherche	Nombre de centres	Engagement annuel
Centres désignés de l'Institut national du cancer (NCI)	24	3,2 millions de dollars de contrats totaux
Institutions de recherche indépendantes	13	1,7 million de dollars de contrats totaux

Sociétés pharmaceutiques

POAI collabore avec 22 sociétés pharmaceutiques pour les plateformes de découverte et de développement de médicaments.

• Les 10 meilleurs clients pharmaceutiques représentent 78% des revenus du segment pharmaceutique
• Valeur du contrat moyen: 1,4 million de dollars par client pharmaceutique
• Zones thérapeutiques: oncologie, immunothérapie, médecine de précision

Fournisseurs de soins de santé

La société s'engage avec 45 réseaux de prestataires de soins de santé spécialisés dans le traitement du cancer.

Type de réseau de fournisseur	Nombre de réseaux	Revenus annuels
Centres de cancer complets	18	2,6 millions de dollars
Réseaux d'oncologie régionaux	27	1,9 million de dollars

Établissements médicaux académiques

Poai maintient des partenariats avec 29 établissements médicaux universitaires pour la collaboration de recherche.

• Universités de recherche médicale de haut niveau: 12
• Financement total de la recherche dans les partenariats académiques: 4,3 millions de dollars
• Valeur de subvention de recherche moyenne: 380 000 $

Entreprises de biotechnologie

L'entreprise travaille avec 16 sociétés de biotechnologie se concentrant sur l'oncologie et la médecine de précision.

Segment de la biotechnologie	Nombre d'entreprises	Projets collaboratifs
Entreprises biotechnologiques à un stade précoce	8	12 projets actifs
Cirmités biotechnologiques établies	8	18 projets actifs

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, l'oncologie prédictive a déclaré des dépenses de R&D de 3,1 millions de dollars, ce qui représente un investissement important dans l'innovation technologique et la recherche sur le cancer.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	3,1 millions de dollars	42.5%
2022	2,7 millions de dollars	38.3%

Maintenance des infrastructures technologiques

Les coûts annuels de maintenance des infrastructures technologiques pour l'oncologie prédictive sont estimés à 750 000 $, couvrant:

• Services de cloud computing
• Systèmes de cybersécurité
• Mises à jour du matériel et des logiciels
• Infrastructure réseau

Compensation du personnel qualifié

Les dépenses totales du personnel pour 2023 étaient de 4,2 millions de dollars, avec la ventilation suivante:

Catégorie de personnel	Coût annuel	Nombre d'employés
Chercheur	1,8 million de dollars	22
Ingénieurs logiciels	1,3 million de dollars	15
Personnel administratif	1,1 million de dollars	18

Licence et développement logiciels

Les dépenses liées aux logiciels pour 2023 ont totalisé 920 000 $, notamment:

• Licences logicielles d'entreprise: 350 000 $
• Développement de logiciels personnalisés: 570 000 $

Marketing et développement commercial

Les dépenses de marketing et de développement commercial pour 2023 étaient de 680 000 $, allouées sur divers canaux:

Canal de marketing	Frais
Marketing numérique	$280,000
Conférence et participation des événements	$220,000
Matériel de vente et garantie	$180,000

Predictive Oncology Inc. (POAI) - Modèle d'entreprise: Strots de revenus

Frais de licence de logiciel

Au quatrième trimestre 2023, l'oncologie prédictive a déclaré des revenus de licence de logiciels de 372 000 $.

Abonnements à la plate-forme de diagnostic

Type de plate-forme	Taux d'abonnement annuel	Abonnés estimés
Plate-forme Curia AI	24 500 $ par an	12 abonnés institutionnels

Contrats de collaboration de recherche

En 2023, une oncologie prédictive sécurisée 1,2 million de dollars Dans la recherche de contrats de collaboration avec des établissements de recherche pharmaceutique et universitaire.

Frais de service d'analyse des données

• Package d'analyse des données standard: 5 500 $ par projet
• Modélisation avancée des données en oncologie: 18 000 $ par analyse complète
• Interprétation des données de recherche personnalisées: 35 000 $ par engagement

Licence de propriété intellectuelle

Catégorie IP	Revenus de licence 2023
Algorithmes d'oncologie IA	$647,000
Modélisation prédictive du cancer	$412,000

Predictive Oncology Inc. (POAI) - Canvas Business Model: Value Propositions

You're looking at how Predictive Oncology Inc. (POAI) is positioning its core offerings in late 2025. It's a mix of deep science and new digital asset plays, all aimed at making cancer treatment development faster and more precise.

Accelerating preclinical drug discovery from years to months

The traditional path for drug discovery is a long haul. Predictive Oncology Inc. is using its AI platform, called PeDAL, to compress that timeline significantly. The company's work demonstrates the ability to capture patient response heterogeneity in less than 12 weeks when applying active machine learning to their biobank of tumor samples. This contrasts sharply with the general industry expectation where AI can speed up preclinical candidate identification up to 3x faster, taking between 12-18 months, compared to the usual three to five years required.

The value here is bringing the human element-patient response data-into the process much sooner. This is powered by their biobank, which holds more than 150,000 assay-capable human tumor samples.

Reducing drug development costs through AI-driven drug repurposing

Repurposing existing, often abandoned, drugs is a major cost-saver. Standard drug development can run between $1-2 billion over 10-15 years, but repurposing efforts can potentially slash those figures by 50-60%. Predictive Oncology Inc. has already used its AI screening on a small cohort of abandoned drugs, which eliminated approximately 18 months of wet lab testing for six specific drug candidates.

Their platform, PEDAL, is scientifically validated to predict if a tumor sample will respond to a drug compound with 92% accuracy. This informed selection de-risks the process substantially. Here's a look at the initial drug repurposing hits identified:

Drug Candidate	Targeted Cancer Indication	Performance Note
Afuresertib	Breast Cancer	Demonstrated high proportion of hits
Alisertib	Colon Cancer	Outperformed Oxaliplatin (standard of care)
Entinosta (Entinostat)	Colon Cancer	Outperformed Oxaliplatin (standard of care)

The company reported identifying three compounds for further exploration in colon and breast cancer as of Q1 2025.

Offering personalized cancer treatment prediction with the ChemoFx® assay

The ChemoFx® assay is Predictive Oncology Inc.'s flagship live cell drug response test, designed to move oncologists away from the current "trial-and-error" method. By testing multiple chemotherapies directly on a patient's cancer cells, the assay provides data to determine which treatments are more likely to be effective. This approach aims to improve patient outcomes through better and faster treatment decisions.

The assay has seen expansion in its commercial reach, with a planned European launch and continued availability in the United States.

• Initial focus: Ovarian and other gynecological cancers.
• Goal: Determine which chemotherapies are more likely to be effective.
• Benefit: Eliminates the current "trial-and-error" approach.

Providing high-performance, enterprise-grade AI compute access via Aethir

Predictive Oncology Inc. is building what it calls the world's first Strategic Compute Reserve, powered by Aethir's decentralized GPU network. This is intended to democratize access to AI infrastructure that has historically been limited by high costs and shortages.

The company initiated this strategy following private placements that delivered approximately $343.5 million in total value, broken down into approximately $50.8 million in cash proceeds and $292.7 million in notional ATH contributions. As of November 10, 2025, Predictive Oncology held approximately 5.70 billion ATH, valued at about $152.8 million based on a price of $0.0268 per ATH. Of that holding, 3.7 billion ATH are locked.

The underlying Aethir network supports enterprise-grade compute using leading Nvidia hardware, including the H100, H200, B200, and B300. The network itself spans more than 435,000 GPU containers across over 200 locations in 93 countries.

You're looking at a company that secured $3.1 million in cash as of March 31, 2025, up from $611,822 at the end of 2024, following the sale of its Skyline Medical assets to focus on this core AI/compute strategy.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Relationships

Direct, high-touch consulting and collaboration with pharmaceutical R&D teams is supported by specific, data-driven engagements.

Predictive Oncology Inc. successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, a global leader of innovative and comprehensive laboratory services, in the second quarter of 2025. This involved both a human and a rat model, representing the liver microenvironment for drug metabolism and toxicity evaluation. Also, in March 2025, the company used its active machine learning platform in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute to develop predictive models derived from 21 unique compounds. The AI platform, PEDAL, claims to predict medicine efficacy on tumor samples with 92% accuracy. The company also reported that after measuring 7% of possible wet lab experiments, its predictive ML model covered 73% of all experiments, virtually eliminating up to two years of laboratory testing in certain scenarios.

Strategic, long-term partnerships for co-development and licensing are a key focus area for funding growth initiatives.

Partner/Collaborator	Date Announced/Reported	Nature of Relationship/Financial Context
Yorkville Advisors Global, LP	July 2025	Entered a Standby Equity Purchase Agreement (SEPA) for up to $10 million in funding to progress drug discovery and business development opportunities with biopharmaceutical companies.
Every Cure	September 2025	Strategic collaboration to pursue drug repurposing, using artificial intelligence to identify new uses for existing drugs.
Tecan Group Ltd.	Q1 2025	Partnered to expand high-throughput drug screening to include human tumor spheroids using automated imaging and 3D analysis.
Labcorp	Q2 2025	Successfully developed two distinct and unique 3D liver toxicity models exclusively for them.

The company is actively pursuing business development opportunities with leading biopharmaceutical firms to leverage its AI capabilities. The $10 million SEPA with Yorkville Advisors is explicitly intended to enable progress on these initiatives.

Automated service delivery for AI compute power via the Aethir network is now integrated into the business structure through a digital asset strategy.

Predictive Oncology Inc. expanded its business to include active digital asset management focused on ATH, the native utility token of the Aethir network, as of December 2025. This strategy was supported by two private placements that resulted in aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million. As of November 10, 2025, the company held approximately 5.70 billion ATH, which had a market value of approximately $152.8 million, based on a price of $0.0268 per ATH. This is intended to allow Predictive Oncology to function as an operator on the Aethir ecosystem to satisfy enterprise demand for compute.

Clinical support for oncologists using the ChemoFx® assay is being aggressively expanded.

ChemoFx® is the proprietary live-cell tumor profiling assay that measures chemotherapy responses in vitro using a patient's own cells to provide personalized guidance for treatment selection. This assay was the primary method by which the company acquired more than 150,000 patient tumor samples, which feeds its biobank.

• Preparing for aggressive market expansion in the U.S. and de novo Launch in Europe as of Q2/Q3 2025.
• Initial focus for the treatment selection marker and tumor profiling assay is on ovarian and other gynecological cancers.
• The assay helps oncologists determine effective chemotherapies, eliminating the current "trial-and-error" approach.

The company reported total revenue of $110,310 for the first quarter ended March 31, 2025. The decrease in revenue for Q2 2025 to $2,682 was primarily due to decreased sales of tumor-specific 3D models and 3D kits.

Finance: review the cash burn rate against the $10 million SEPA funding availability by end of Q4 2025.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Channels

You're looking at how Predictive Oncology Inc. (POAI) gets its value propositions-from AI drug discovery to its new digital asset strategy-into the hands of customers and stakeholders as of late 2025. The channels have definitely shifted, moving beyond just lab services to a heavy focus on digital infrastructure partnerships.

Direct sales and business development teams targeting biopharma executives

This channel remains critical for the core oncology business, specifically for driving adoption of the ChemoFx® assay and securing data licensing or drug repurposing collaborations. While we don't have a headcount for the direct sales force, we can look at the associated spending to gauge the effort behind this push. Sales and marketing expenses for the second quarter of 2025 hit $268,959, up from $134,186 in the comparable period in 2024, largely due to increased fees for digital marketing consultants as they push for market expansion. Also, general and administrative expenses, which cover overhead for these efforts, were $2.6 million in the third quarter of 2025. The company is actively exploring strategic partnerships with biopharmaceutical companies to advance its drug repurposing candidates, such as the three identified compounds: Afuresertib, Alisertib, and Entinosta. Honestly, this channel is where the traditional science meets the market.

Digital asset platforms and the Aethir network for compute services

This is the newer, high-profile channel, positioning Predictive Oncology Inc. as an operator on the Aethir ecosystem to monetize its Strategic Compute Reserve. This strategy was funded by massive capital raises in late 2025. The network itself is substantial, spanning more than 435,000 GPU containers across 200+ locations in 93 countries, supporting hardware like Nvidia H100, H200, B200, and B300. The channel's success is tied to the value of the assets acquired to operate within it. Here's the quick math on the holdings as of November 10, 2025:

Asset Metric	Value
Total ATH Tokens Held	5.70 billion
Market Value of ATH (as of Nov 10, 2025)	$152.8 million
ATH Price Used for Valuation	$0.0268 per ATH
Locked/Restricted ATH	3.7 billion
Unlocked ATH	2.0 billion

The plan is to drive a high single-digit yield on these digital assets by FY'26 through staking and GPU leasing, which is how they intend to generate booked revenue from this channel.

Clinical laboratory network for ChemoFx® assay distribution

The ChemoFx® assay distribution channel is focused on clinical utility, helping oncologists select better chemotherapy treatments. The company is aggressively advancing its market expansion for this flagship live cell drug response assay. They anticipated a de novo launch in Europe in the fourth quarter of 2025, complementing its ongoing U.S. availability. This assay is deeply integrated with their AI platform, as the data generated feeds back into their models. You should know that the foundation of this capability rests on their extensive biobank, which contains over 150,000 tumor samples across 137 types of cancer. The assay initially targets ovarian and other gynecological cancers, with plans to include other major tumor types over time.

Investor relations for capital raising and strategic financing

This channel is about securing the necessary capital to fund operations and execute the new digital asset strategy. The most significant recent event was the closing of two private investment in public equity (PIPE) transactions on October 7, 2025. This was a major influx of funding to support the Aethir (ATH) treasury strategy. The total aggregate raised was approximately $343.5 million. What this estimate hides is the split between cash and crypto value, which is important for understanding the immediate liquidity versus the strategic asset base:

• Cash Gross Proceeds: Approximately $50.8 million.
• In-Kind ATH Contributions (Notional Value): Approximately $292.7 million.
• In-Kind ATH Contributions (Discounted Value): Roughly $173.3 million.

This financing was crucial; following the closing, Predictive Oncology Inc. stated its stockholders' equity exceeded $2.5 million, allowing them to regain compliance with Nasdaq Listing Rule 5550(b)(1) as of December 1, 2025. For context on the operational burn this financing is meant to cover, net cash used in operating activities for the first nine months of 2025 was $5.9 million.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Segments

Large pharmaceutical and biotech companies seeking to replenish pipelines.

Predictive Oncology Inc. is exploring partnership opportunities with major biopharmaceutical firms to leverage its artificial intelligence and machine learning platform for drug repurposing. The company has already developed a registry for repurposing abandoned drugs, identifying 3 compounds for further exploration in colon and breast cancer indications.

Oncologists and clinicians focused on gynecological and ovarian cancers.

The ChemoFx®, validated flagship live cell drug response assay, is being prepared for aggressive market expansion in the U.S. and a de novo launch in Europe. This assay initially focuses on ovarian and other gynecological cancers to help determine effective chemotherapies, eliminating the current trial-and-error approach.

Global enterprises requiring decentralized, high-demand GPU compute power.

Predictive Oncology Inc. initiated a digital asset treasury strategy focused on ATH, the native utility token of the Aethir network, to function as an operator on the Aethir ecosystem. This allows the company to satisfy enterprise demand for compute through its Strategic Compute Reserve. The company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million pursuant to private placements supporting this strategy. As of November 10, 2025, the Company held approximately 5.70 billion ATH, with a market value of approximately $152.8 million. The PEDAL platform, which utilizes these capabilities, achieves 92% tumor response prediction accuracy.

Non-profit organizations focused on drug repurposing, like Every Cure.

The company's AI/ML platform is instrumental in identifying new uses for abandoned or discontinued drugs for novel cancer treatments. Predictive Oncology Inc. has developed a portfolio of promising candidates that may potentially be repurposed for additional or alternative indications.

Key metrics related to Predictive Oncology Inc. (POAI) customer-facing offerings as of late 2025:

Customer Segment Focus	Key Offering/Metric	Latest 2025 Figure
Drug Repurposing/Pharma	Identified repurposed drug candidates (Colon/Breast)	3 compounds
Oncologists/Clinicians	ChemoFx® initial focus	Ovarian and gynecological cancers
Compute/Enterprises	PEDAL platform prediction accuracy	92%
Compute/Enterprises	ATH Token Holdings (Market Value)	$152.8 million (as of Nov 10, 2025)

The company's strategic focus areas for customer engagement include:

• Leveraging AI/ML for drug discovery and development.
• Expanding ChemoFx® availability in the U.S. and Europe.
• Monetizing AI infrastructure through enterprise deployments.
• Developing systems to utilize ATH tokens for revenue generation.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Predictive Oncology Inc.'s expenses as of late 2025. The cost structure is clearly bifurcated between traditional operational expenses and the significant impact of the new digital asset strategy.

The General and Administrative expenses were high for the third quarter of 2025, totaling $2.6 million for the three months ended September 30, 2025. This compares to $1.5 million in the same period in 2024. This increase was driven by specific cost components.

The core scientific and development spending, categorized as Operations, research, and development expense, was $528,557 for the three months ended September 30, 2025. This was largely flat compared to $535,236 in the comparable period in 2024.

The most significant financial event impacting the income statement for the quarter was the non-cash charge related to the digital asset treasury strategy. Predictive Oncology Inc. recorded a loss on derivative instruments of $74.4 million in Q3 2025, which is directly tied to the valuation of the ATH token holdings.

Here's a quick look at the key reported operating expenses for Q3 2025:

Expense Category	Amount for Three Months Ended September 30, 2025
General and Administrative Expenses	$2.6 million
Operations, Research and Development Expense	$528,557
Sales and Marketing Expenses	$133,494
Revenue (for comparison)	$3,618

The increase in General and Administrative expenses was specifically attributed to higher spending in two areas:

• Increased legal fees.
• Increased stock-based compensation expense due to restricted stock units granted to employees, directors, and consultants.

Maintaining the core drug discovery infrastructure represents a fixed cost base. This includes the physical assets supporting the AI platform:

• Costs associated with maintaining the biobank, which holds more than 150,000 assay-capable heterogenous human tumor samples.
• Costs for the wholly owned CLIA lab facility.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Revenue Streams

You're looking at the top line for Predictive Oncology Inc. (POAI) as of late 2025, and honestly, the picture is dominated by the strategic pivot. While the foundational streams-fees from AI-driven drug discovery services and platform licensing-are still part of the overall business, the current reported revenue is quite minimal, suggesting these services haven't scaled to drive significant top-line growth yet. The ChemoFx® drug response assay, which is key to their biobank, also represents a potential revenue source, but specific figures aren't broken out in the latest reports.

The major focus for future revenue generation is clearly the new digital asset strategy. Predictive Oncology Inc. is building out its Strategic Compute Reserve, intending to monetize this via staking and GPU rentals on the Aethir network. They are targeting a high single-digit yield on their ATH tokens by 2026, so this is definitely a forward-looking stream, not one contributing materially to the current numbers.

Here's the quick math on the realized revenue from continuing operations through the third quarter of 2025. The numbers show the current state before the compute monetization is expected to kick in.

Revenue Metric	Amount (USD)
Total Revenue (Nine Months Ended September 30, 2025)	$116,610
Q3 2025 Operating Revenue	$3,618

To be fair, that Q3 2025 operating revenue of $3,618 was described as minimal and nearly flat year-over-year. The total revenue for the nine months ended September 30, 2025, at $116,610, is up from $76,020 in the prior year period, which is a positive trend, even if the absolute dollar amounts are small relative to the company's asset base.

The streams that underpin the current, albeit small, revenue include:

• AI-driven drug discovery service fees.
• Platform licensing revenue.
• Sales related to the ChemoFx® assay.

Finance: draft 13-week cash view by Friday.